These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26799060)

  • 21. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 24. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian approach to non-inferiority trials for normal means.
    Gamalo MA; Wu R; Tiwari RC
    Stat Methods Med Res; 2016 Feb; 25(1):221-40. PubMed ID: 22619277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian subgroup analysis with a zero-enriched Polya Urn scheme.
    Sivaganesan S; Laud PW; Müller P
    Stat Med; 2011 Feb; 30(4):312-23. PubMed ID: 21225894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The experience in the FDA's Center for Devices and Radiological Health with Bayesian strategies.
    Campbell G
    Clin Trials; 2005; 2(4):359-63; discussion 364-78. PubMed ID: 16281433
    [No Abstract]   [Full Text] [Related]  

  • 28. Guest editors' note: Bayesian approaches for medical product evaluation--today and tomorrow.
    Li X; Xu Y
    J Biopharm Stat; 2011 Sep; 21(5):869-70. PubMed ID: 21830919
    [No Abstract]   [Full Text] [Related]  

  • 29. Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.
    Cloutier LM; Sirois S
    Drug Discov Today; 2008 Jun; 13(11-12):536-42. PubMed ID: 18549981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequentist versus Bayesian approaches to multiple testing.
    Sjölander A; Vansteelandt S
    Eur J Epidemiol; 2019 Sep; 34(9):809-821. PubMed ID: 31087218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative approaches to clinical development and trial design.
    Orloff JJ; Stanski D
    Ann Ist Super Sanita; 2011; 47(1):8-13. PubMed ID: 21430331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The choice of sample size: a mixed Bayesian / frequentist approach.
    Pezeshk H; Nematollahi N; Maroufy V; Gittins J
    Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are Bayes' days upon us? Statistical methods could change the conduct of clinical trials.
    Beckman M
    J Natl Cancer Inst; 2006 Nov; 98(21):1512-3. PubMed ID: 17077349
    [No Abstract]   [Full Text] [Related]  

  • 34. Bayesian statistical methods in public health and medicine.
    Etzioni RD; Kadane JB
    Annu Rev Public Health; 1995; 16():23-41. PubMed ID: 7639872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive checking for Bayesian interim analyses in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Sep; 29(5):740-50. PubMed ID: 18571477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study.
    Jadhav PR; Zhang J; Gobburu JV
    Pharm Stat; 2009; 8(3):216-24. PubMed ID: 19610013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bridging data across studies using frequentist and Bayesian estimation.
    Zhang T; Lipkovich I; Marchenko O
    J Biopharm Stat; 2017; 27(3):426-441. PubMed ID: 28287342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
    Ionan AC; Clark J; Travis J; Amatya A; Scott J; Smith JP; Chattopadhyay S; Salerno MJ; Rothmann M
    Ther Innov Regul Sci; 2023 May; 57(3):436-444. PubMed ID: 36459346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.